Advisor Group Holdings, Inc. Curis Inc Transaction History

Advisor Group Holdings, Inc.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 10, 2023	BUY	$0.57 - $0.99 $683 - $1,188	1,200 Added 3.75%	33,200 $27,000
Q4 2022 Feb 10, 2023	SELL	$0.47 - $17.22 $2 - $86	-5 Reduced 0.02%	32,000 $17,000
Q3 2022 Nov 14, 2022	SELL	$0.74 - $15.01 $25 - $525	-35 Reduced 0.11%	32,005 $22,000
Q2 2022 Aug 10, 2022	BUY	$0.71 - $2.43 $14,200 - $48,600	20,000 Added 166.11%	32,040 $32,000
Q1 2022 May 04, 2022	BUY	$2.31 - $5.13 $10,395 - $23,085	4,500 Added 59.68%	12,040 $29,000
Q3 2021 Nov 05, 2021	BUY	$6.94 - $8.85 $13,880 - $17,700	2,000 Added 36.1%	7,540 $58,000
Q2 2021 Aug 02, 2021	BUY	$7.45 - $16.27 $298 - $650	40 Added 0.73%	5,540 $44,000
Q1 2021 May 13, 2021	BUY	$8.78 - $12.8 $13,073 - $19,059	1,489 Added 37.12%	5,500 $62,000
Q4 2020 Feb 10, 2021	BUY	$1.08 - $8.2 $4,293 - $32,594	3,975 Added 11041.67%	4,011 $33,000
Q3 2020 Nov 12, 2020	BUY	$0.95 - $1.42 $10 - $15	11 Added 44.0%	36 $0
Q2 2020 Aug 14, 2020	SELL	$0.63 - $1.7 $121 - $328	-193 Reduced 88.53%	25 $0
Q1 2020 May 18, 2020	BUY	$0.67 - $1.85 $146 - $403	218 New	218 $0

Ticker CRIS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 91,814,704
Market Cap $393M
Description
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myel...

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

Stay updated on Advisor Group Holdings, Inc. with notifications on news.